Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: Results of a substudy from a comparative trial

AIDS

Volumn 16, Issue 18, 2002, Pages 2447-2454

  Joly, Véronique ^a   Flandre, Philippe ^b   Meiffredy, Vincent ^b   Leturque, Nicolas ^b   Harel, Marine ^b   Aboulker, Jean Pierre ^b   Yeni, Patrick ^a  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Antiretroviral therapy; Clinical trial; Lipodystrophy; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD VESSEL INJURY; BUTTOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FACE MALFORMATION; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEG DISEASE; LIPOATROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY CONSTITUTION; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INDINAVIR; LAMIVUDINE; MALE; MIDDLE AGED; RISK FACTORS; STAVUDINE; ZIDOVUDINE;

EID: 0037032941     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200212060-00010     Document Type: Article

References (25)

1. Hogg RS, Heath KV, Schechter MT, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner IS. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450-454.
2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatients Study Investigators. N Engl J Med 1998; 352:1725-1730.
3. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA, A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F59.
4. Lichtenstein KA, Ward DJ, Moorman A, Delaney KM, Young B, Palella FJ Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15: 1389-1398.
5. Madge S, de Kinloch LS, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999; 13:735-737.
6. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang J-M, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside-analogue therapy. AIDS 1999; 13:1659-1667.
7. Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15:231-239.
8. Saint Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study. AIDS 2000; 14:37-49.
9. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. Lancet 2001; 357:592-598.
10. Chẽne G, Angelini E, Cotte L, Lang JM, Morlat P, Rancinan C, et al. Rõle of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34:649-657.
11. Van der Valk M, Gisolf EH, Reiss P, Wit FWNM, lapour A, Weverling GJ, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001; 15:847-855.
12. Law MG, Emery S, French M, Carr A, Chuah J, Cooper D. Lipodystrophy and metabolic abnormalities in a cross-sectional study of participants in randomised controlled studies of combination antiretroviral therapy (ARV). Antiviral Ther 2000; 5:18.
13. Joly V, Flandre P, Meiffredy V, Brun-Vézinet F, Gastaut IA, Gouiard C, et al., Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-Infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudíne or protease inhibitors (Novavir trial). Antimicrob Agents Chemother 2002; 46:1906-1913.
14. Agresti A. Categorical data analysís. New York: Wiley & Sons; 1990.
15. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999; 353: 2093-2099.
16. Martinez E, Bianchi L, Garcia-Viejo MA, Bru C, Gatell JM, Sonographic assessment of regional fat in HIV-1-infected people. Lancet 2000; 356:1412-1413.
17. Bogner JR, Vielhauer V, Beckman RA, Michl G, Wille L, Salzberger B, Goebel FD. Stavudine versus zidovudine and the development of lipodystrophy. I Acquir Immune Defic Syndr 2000; 23:35-43.
18. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reversetranscriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
19. Carr A, Miller J, Law M, Cooper D. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14:F25-F32.
20. Gervasoni C, Ridolfo AL, Trifiro G, Santambrogio S, Norbiato G, Musicco M, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13:465-471.
21. Mulligan K, Tai VW, Algren H, Abrams DI, Leiser RJ, Lo JC, Schambelan M. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. I Acquir Immune Defic Syndr 2001; 26:443-448.
22. Galli M, Ridolfo AL, Gervasoni C, Ravasio L, Adomi F, Moroni M, Incidence of fat tissue abnormalities in protease inhibitor-naive patients treated with NRTI combinations. Antivir Ther 1999; 4 (Suppl. 2):43-44.
23. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-associated mitochondrial toxicity as an etiology for lipodystrophy. AIDS 1999; 13:2311-2312.
24. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
25. Wallace D. Mitochondrial genetics: A paradigm for ageing and degenerative diseases? Science 1992; 256:628-632.